Bigger, Bolder, SMAR: Decoding China's All-In-One Regulatory Agency
Executive Summary
A new era began April 10 with disappearance of China FDA and kickoff of State Administration for Market Regulation (SMAR), the so-called 'One-Stop' regulatory agency. Will the CFDA's innovation-encouraging policies continue? How will the new agency balance innovation and enforcement? Pink Sheet offers preliminary answers to these key questions and decode the new SMAR from five important aspects.
You may also be interested in...
China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
China Shows More Of An Open Door To Overseas Medtech Industry
China's influence on global medtech regulation and the country's continuing emergence on the world stage will be felt increasingly in the coming years. But while China may be less inclined to exclude big medtech multinationals, it feels no compulsion to harmonize totally with the US and/or EU systems.
Mehta Analysis: China, A Populist Pharma Power
With money pouring into biopharma in China, and regulatory reforms favoring market growth and R&D speed, western firms should watch their backs, warns Viren Mehta, founding partner of Mehta Partners LLC.